Recordati Rare Diseases Inc., the makers of CYSTADROPS, launched a website to support the launch of the eye treatment...
Read moreBy Cystinosis Research Network
October 13, 2020
In a statement from Leadient Biosciences on October 9th, the company announced an availability shortage may impact cystinosis patients...
Read moreBy Cystinosis Research Network
October 9, 2020
In April, the Cystinosis Network Europe adapted their international conference to the restrictions set forth by COVID-19. The result...
Read moreBy Cystinosis Research Network
September 29, 2020
A newly approved eye drop solution will expand treatment options for people living with cystinosis in Canada. Targeting corneal...
Read moreThe Cystinosis Research Network (CRN) is pleased to welcome two newly appointed leaders whose professional expertise, lived experience, and...
Read moreNews from Leadiant regarding new storage of Cystaran (cysteamine ophthalmic solution) 0.44%. Beginning December 22, 2025, shipments of Cystaran...
Read moreThe next phase of clinical development for the CF10 prodrug to treat cystinosis has been announced. The Cystinosis Foundation...
Read moreThe Neuromuscular Clinic at Massachusetts General Hospital (MGH) led by Dr. Reza Seyedsadjadi, is currently enrolling participants for a...
Read moreEmory University in Atlanta, Georgia, is actively recruiting for the Cohort 0 control groupin the CYStem clinical trial. While...
Read more